

Final checklist of items to assess quality of randomized controlled trials of nonpharmacological treatment.

1. Was the generation of allocation sequences adequate?	Yes / No / Unclear
2. Was the treatment allocation concealed?	Yes / No / Unclear
3. Were details of the intervention administered to each group made available ¹ ?	Yes / No / Unclear
4. Were care providers' experience or skill ² in each arm appropriate ³ ?	Yes / No / Unclear
5. Was participant (ie, patients) adherence assessed quantitatively ⁴ ?	Yes / No / Unclear
6. Were participants adequately blinded?	Yes No, because blinding is not feasible No, although blinding is feasible Unclear
6.1. If participants were <u>not adequately blinded</u>	
6.1.1. Were all other treatments and care (ie, co-interventions) the same in each randomized group?	Yes / No / Unclear
6.1.2. Were withdrawals and lost to follow-up the same in each randomized group?	Yes / No / Unclear
7. Were care providers or persons caring for the participants adequately blinded?	Yes No, because blinding is not feasible No, although blinding is feasible Unclear
7.1. If care providers were <u>not adequately blinded</u>	
7.1.1. Were all other treatments and care (ie, co-interventions) the same in each randomized group?	Yes / No / Unclear
7.1.2. Were withdrawals and lost to follow-up the same in each randomized group?	Yes / No / Unclear
8. Were outcome assessors adequately blinded to assess the primary outcomes?	Yes No, because blinding is not feasible No, although blinding is feasible Unclear
8.1. If outcome assessors were <u>not adequately blinded</u> , were specific methods used to avoid ascertainment bias (systematic differences in outcome assessment) ⁵	Yes / No / Unclear
9. Was the follow-up schedule the same in each group ⁶ ?	Yes / No / Unclear
10. Were the main outcomes analyzed according to the intention-to-treat principle?	Yes / No / Unclear

¹ The answer should be “yes” for this item if these data were either described in the report or made available for each arm (reference to a preliminary report, online addendum etc.)

² Care providers' experience or skill will be assessed only **for therapist-dependent interventions** (i.e., interventions where the success of the treatment are directly linked to care providers' technical skill). For other treatment, this item is **not relevant** and should be **removed** from the checklist or answered “unclear”.

³ Appropriate experience or skill should be determined according to published data, preliminary studies, guidelines, run-in period or a group of experts and **prespecified** in the protocol for each study arm before the beginning of the survey.

⁴ Treatment adherence will be assessed only **for treatments necessitating iterative interventions** (e.g., physiotherapy that supposes several sessions, in contrast to a “one-shot” treatment such as surgery). For **one-shot treatment**, this item is **not relevant** and should be **removed** from the checklist or answered “unclear”

⁵ The answer should be “yes” for this item, if the main outcome is **objective or “hard”** or outcomes were assessed by a **blinded or at least an independent endpoint review committee** or outcomes were assessed by an **independent outcome assessor trained** to perform the measurements in a standardized manner or the outcome assessor was **blinded to the study purpose and hypothesis**.

⁶ This item is not relevant for trials in which **follow-up is part of the question**. For example, this item is not relevant for a trial assessing frequent versus less frequent follow-up for cancer recurrence. In these situations, this item should be **removed** from the checklist or answered “unclear”.